The Prime Therapeutics Report is your trusted source for the latest in managed care strategies, specialty drug trends and payer-focused insights. The Summer 2025 issue features a cover story on HIV...

July 15, 2026 publications Summer 2026 Prime Therapeutics Report Explore timely specialty insights for managed care, including autoimmune biosimilars, policy developments, pipeline activity,...

The content in this publication is not a substitute for professional medical advice. For questions regarding any medical condition or if you need medical advice, please contact your health care...

WEIGHT MANAGEMENT CORNER The American Heart Association (AHA) has published a Presidential Advisory forecasting the extent of cardiovascular disease (CVD) and stroke expected in the U.S. through...

SAVINGS PER CASE $11,500 An employer group with 7,000 lives implemented HighTouchRx. They saw savings of $194,300, with HighTouchRx providing an ROI of 5:1.4 Since its launch, HighTouchRx has saved...

The American Gastroenterological Association (AGA) has released a clinical practice guideline on management of gastroparesis, including recommendations for diagnosis and effective treatment (e.g.,...

Gene therapy harnesses the body’s capacity to heal itself

Managed Healthcare Executive: Prior authorization using integrated medical claims data helps diabetes patients get medications faster, with two-thirds processed automatically by July 2025 in this...

The CDC is reporting influenza-like illness (ILI) for the week ending March 15, 2025 (week 11). Seasonal influenza activity remains increased across the U.S. but has decreased for five consecutive...

Understanding your data INO-3107 is a DNA immunotherapy composed of a plasmid encoding for antigens from both HPV-6 and HPV-11 as well as a plasmid encoding for an interleukin-12 (IL-12) immune...

Jan. 26, 2026 – folic acid oral solution (Quiofic) 505(b)(2) NDA approval; other formulations of folic acid include the following: oral capsule, oral tablet, solution for injection and an OTC oral...

PUBLICATIONS FDA Decisions Expected: January 2026 Your monthly synopsis of new drugs expected to hit the market All brand names are property of their respective owners. References SERENA-6 trial:...

Oct. 29, 2025 – denosumab-desu (Jubereq) BLA approval; the 120 mg/1.7 mL single-dose vial for SC use has received FDA approval as an interchangeable biosimilar to the same presentation of denosumab...

New biosimilars Feb. 26, 2026 – zongertinib (Hernexeos) Boehringer Ingelheim; kinase inhibitor; Accelerated Approval, Assessment Aid, Breakthrough Therapy, Commissioner's National Priority Voucher...

From next-gen CFTR modulators to gene therapy and real-world drug impact, cystic fibrosis care is constantly evolving. Maryam Tabatabai, PharmD, of Prime Therapeutics, explains how innovative...

Prime Therapeutics Report shares more about single-treatment gene therapies and proper management

Prime study finds the cost of GLP-1s continues to be a significant driver of total cost of care, which remained $4,490 higher in Year 3 compared to a matched control group

Drug information happenings publications Trending Topics & Drug Approvals: June 2026 Your source for the latest drug information highlights May 15, 2026 — baxdrostat (Baxfendy) NDA approval;...

Clemidsogene lanparvovec (RGX-121) is an investigational, one-time intracisternal adeno-associated virus serotype 9 (AAV9) gene therapy delivering the iduronate-2-sulfatase (IDS) gene directly to...

The information provided has been developed based on available information as of March 3, 2025. This therapy is NOT FDA approved, and content may change as more information becomes available....